Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Koninklijke Philips (PHG) Raw Materials (2016 - 2023)

Koninklijke Philips' quarterly Raw Materials came in at $1.4 billion in Q4 2023, down 10.42% year-on-year from $1.6 billion in Q4 2022, and down 10.42% quarter-over-quarter from $1.6 billion in Q4 2022.

Koninklijke Philips has reported Raw Materials for 8 years, with the latest figure at $1.4 billion in Q4 2023.

  • For the quarter ending Q4 2023, Raw Materials fell 10.42% year-over-year to $1.4 billion; the trailing twelve-month figure through Dec 2023 stood at $1.4 billion (down 10.42% YoY), and the FY2023 full-year result was $1.4 billion, down 10.42% from the prior year.
  • Raw Materials for Q4 2023 stood at $1.4 billion, down from $1.6 billion in the prior quarter.
  • The five-year high for Raw Materials was $1.6 billion in Q4 2022, with the low at $997.3 million in Q4 2019.
  • Average Raw Materials over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2021.
  • Year-over-year, Raw Materials grew 20.24% in 2022 and retreated 10.42% in 2023.
  • Tracing PHG's Raw Materials over 5 years: stood at $997.3 million in 2019, then climbed by 18.59% to $1.2 billion in 2020, then advanced by 10.55% to $1.3 billion in 2021, then gained by 20.24% to $1.6 billion in 2022, then declined by 10.42% to $1.4 billion in 2023.
  • The last three Raw Materials figures came in at $1.4 billion (Q4 2023), $1.6 billion (Q4 2022), and $1.3 billion (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 1.41 Bn
Dec 31, 2022 1.57 Bn
Dec 31, 2021 1.31 Bn
Dec 31, 2020 1.18 Bn
Dec 31, 2019 997.31 Mn
Dec 31, 2018 999.86 Mn
Dec 31, 2017 841.86 Mn
Dec 31, 2016 1.12 Bn